文献速递淋巴瘤

IGHV突变绝对百分比偏差而非98%截断值可预测接受氟达拉滨、环磷酰胺和利妥昔单抗治疗的慢性淋巴细胞白血病患者的生存

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
PubMed 文献 · Br J Haematol · 2017-11-21

该研究在203例接受一线FCR方案(氟达拉滨、环磷酰胺、利妥昔单抗)治疗的CLL患者中分析IGHV%的预后意义,中位随访10年,发现IGHV%作为连续变量与PFS和OS显著相关(P<0.001);并在323例方案外FCR治疗患者及总队列(n=535)中验证,多因素分析显示IGHV%较高与更优的PFS和OS呈递增关联。

要点

  • IGHV%作为连续变量与FCR治疗CLL患者的PFS和OS显著相关(P<0.001)。
  • 在203例一线FCR试验患者、323例方案外FCR患者及总队列(n=535)中验证了该关联。
  • 多因素分析显示IGHV%较高与更优的PFS和OS呈递增关联(两个队列P均<0.001)。

核心结论

  • 数据提示IGHV%在接受FCR治疗的CLL患者中为连续变量。

研究设计与样本

  • 分析203例入组原始一线FCR试验的CLL患者,中位随访10年。
  • 在323例方案外接受FCR治疗的患者及总队列(n=535)中验证。

主要发现

  • 采用Cox比例风险模型,IGHV%作为连续变量与PFS和OS显著相关(P<0.001)。
  • 多因素分析显示连续趋势,两个FCR治疗队列中IGHV%较高与更优的PFS和OS呈递增关联(P<0.001,两个队列)。

关键数值与推荐

  • 目前常规使用2%偏差或与胚系序列98%同一性作为截断值将CLL患者二分为突变组和未突变组。
  • 不同研究中报道了1-5%不等的IGHV%截断值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The degree of somatic hypermutation, determined as percent deviation of immunoglobulin heavy chain gene variable region sequence from the germline (IGHV%), is an important prognostic factor in chronic lymphocytic leukaemia (CLL). Currently, a cut-off of 2% deviation or 98% sequence identity to germline in IGHV sequence is routinely used to dichotomize CLL patients into mutated and unmutated groups. Because dissimilar IGHV% cut-offs of 1-5% were identified in different studies, we wondered whether no cut-off should be applied and IGHV% treated as a continuous variable. We analysed the significance of IGHV% in 203 CLL patients enrolled on the original frontline fludarabine, cyclophosphamide and rituximab (FCR) trial with a median of 10 years follow-up. Using the Cox Proportional Hazard model, IGHV% was identified as a continuous variable that is significantly associated with progression-free (PFS) and overall survival (OS) (P < 0·001). Furthermore, we validated this finding in 323 patients treated with FCR off-protocol and in the total cohort (n = 535). Multivariate analysis revealed a continuous trend. Higher IGHV% levels were incrementally associated with favorable PFS and OS in both FCR-treated cohorts (P < 0·001, both cohorts). Taken together, our data suggest that IGHV% is a continuous variable in CLL patients treated with FCR.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jain P, Nogueras González GM, Kanagal-Shamanna R, et al. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2017. PMID: 29164608. doi:10.1111/bjh.15018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。